Organ Transplant Diagnostics Market – A Global and Regional Analysis: Focus on Offering, Transplant, Application, Technology, End User, and Region – Analysis and Forecast, 2021-2031

$5,250$8,100

the organ transplant diagnostics industry to be one of the most rapidly evolving and dynamic markets, and the global market for organ transplant diagnostics is predicted to grow at a CAGR of 10.92% over the forecast period of 2021-2031.

Clear

Description

Market Report Coverage – Organ Transplant Diagnostics Market

Market Segmentation

• Offering – Products (Kits and Assays and Consumables) and Services
• Transplant – Solid Organ Transplant and Stem Cell Transplant
• Application – Diagnostics (Donor Testing and Recipient Testing) and Translational Research
• Technology – Molecular Technologies, Serology, Flow Cytometry, and Other Technologies
• End User – Hospitals and Transplant Centers, Academic and Research Institutions, Reference Laboratories, and Other End Users

Regional Segmentation

• North America – U.S., and Canada
• Europe – Germany, France, U.K., Italy, Spain, Switzerland, and Rest-of-Europe
• Asia-Pacific – China, India, Japan, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific
• Latin America – Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World

Market Growth Drivers

• Rising Number of Organ Transplant Procedure
• Strategic Initiatives by Key Market Players
• Favorable Regulatory Scenario

Market Challenges

• High Cost of Organ Transplant Procedure and Diagnostics
• Lack of Knowledge Dissemination and Reluctance Toward Organ Transplants

Market Opportunities

• Technological Advancement in Transplant Diagnostics
• Increasing Awareness Regarding Transplants in High potential Market

Key Companies Profiled

Thermo Fisher Scientific Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Inc., Laboratory Corporation of America Holdings, bioMérieux S.A., CareDx, Inc., ARUP Laboratories, Abbott Laboratories, Quest Diagnostics Incorporated, Eurofins Scientific, Illumina, Inc., OPKO Health, Novacyt Group, Immucor, Inc.

Key Questions Answered in this Report:

• How is organ transplant diagnostics revolutionizing the field of transplant care?
• What are the major market drivers, challenges, and opportunities in the global organ transplant diagnostics market?
• What are the underlying structures resulting in the emerging trends within the global organ transplant diagnostics market?
• How did the COVID-19 pandemic impact the global organ transplant diagnostics ecosystem?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of organ transplant diagnostics?
• What are the potential entry barriers, which are expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:

o Offering (products and services)
o Transplant (solid organ transplant and stem cell transplant)
o Application (diagnostics and translation research)
o Technology (molecular technologies, serology, flow cytometry and other technologies)
o End User (hospitals and transplant centers, academic and research institutions, and reference laboratories)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)

• What are the growth opportunities for the organ transplant diagnostics companies in the region of their operation?
• Who are the leading players with significant offerings in the global organ transplant diagnostics market?
• Which companies are anticipated to be highly disruptive in the future, and why?

Executive Summary

Organ transplantation is one of the most preferred treatment options for patients suffering from end-stage chronic diseases, which further leads to organ dysfunction. Organ transplant diagnostics has become an integral component for conducting clinical assessments of various attributes associated with donor organ’s screening and recipient surveillance.

The increase in the healthcare burden due to the growing number of chronic conditions coupled with the rising awareness among patients regarding the clinical outcomes associated with organ transplants has led to the development of high-fidelity transplant diagnostic approaches which could offer long-time survival.

As organ donor and recipient screening are mandatory, emerging and established companies operating in the market are massively invest in the development of products and services based on cutting-edge technologies. Additionally, advancing molecular assay technologies harnessing increasing knowledge of transplant-associated biomarkers are now on the verge of revolutionizing approaches to healthcare and medicine worldwide.

Innovations such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) enable accurate quantification and analysis of transplant-associated biomarkers, which are difficult to be identified and measured using conventional serology-based methodologies.

Therefore, manufacturers and service providers operating in the organ transplant diagnostics landscape are massively investing in research and development (R&D) to develop and expand their respective portfolios, which is expected to offer better clinical outcomes.

As the next frontier of precision medicine, the global organ transplant diagnostics market showcases enormous potential to completely revolutionize the field of transplant care worldwide.

Figure: U.S. Solid Organ and Bone Marrow Transplant Procedures (2017-2020)

organ transplant diagnostics market

the global organ transplant diagnostics market is projected to reach $XX million by 2031, growing from $XX million in 2020, at a CAGR of XX% during the forecast period 2021-2031. Growth in this market is expected to be driven by the rising number of organ transplant procedure, strategic initiatives by key market players, and favorable regulatory scenarios.

However, factors such as the high cost of organ transplant and transplant diagnostics products and lack of knowledge dissemination, and reluctance toward organ transplants are some of the significant challenges restraining the growth of the global organ transplant diagnostics market.

Impact Analysis of Market Drivers and Market Challenges on the Global Organ Transplant Diagnostics Market

Impact Analysis of Market Drivers and Market Challenges on the Global Organ Transplant Diagnostics Market

With respect to the overall market share, the services segment held the largest share, XX%, of the global organ transplant diagnostics market in 2020. This trend is expected to continue during the forecast period 2021-2031, with the segment anticipated to hold a XX% share in 2031.

The high share of the services segment is majorly due to the rising number of organ transplant procedures, increasing focus on organ donor screening, rising awareness pertaining to post-transplant care, and increasing emphasis on the adoption of precision medicine strategies, among others.

In 2020, the global organ transplant diagnostics market (by transplant) was dominated by solid organ transplants, with a massive market share of XX%. This trend is expected to continue during the forecast period 2021-2031, with the segment anticipated to hold a XX% share in 2031.

This is primarily due to the growing prevalence of chronic medical conditions associated with the kidney, lungs, and heart, increasing awareness among patients regarding the clinical benefits of solid organ transplants, increasing incidence of transplant-associated infectious diseases, and increasing research on new product developments, among others.

In 2020, the global organ transplant diagnostics market (by application) was dominated by recipient testing, which held a share of XX%. This trend is expected to continue during the forecast period 2021-2031, with the segment anticipated to hold a XX% share in 2031.

This is primarily due to the growing emphasis on post-transplant surveillance coupled with the increasing cases of opportunistic infectious disease manifestation due to the administration of a high dosage of immunosuppressant therapies.

However, the donor testing segment is anticipated to witness the highest growth of XX% during the forecast period, 2021-2031. This is majorly due to the presence of robust guidelines pertaining to organ donor screening, rising focus on donor-derived organ quality, and growing investments by the companies for the development of organ donor screening products, among others.

As of 2020, the global organ transplant diagnostics market (by technology) was dominated by molecular technologies, holding a massive market share of XX%. This trend is expected to continue during the forecast period 2021-2031, with the segment anticipated to hold a XX% share in 2031.

This high share of molecular technologies is majorly due to its clinical utility coupled with the increasing adoption of PCR- and NGS-based organ transplant diagnostic products and services by the end users. Additionally, the growing adoption of molecular technologies by academic and research institutions for conducting cutting-edge research in the field of transplant diagnostics has further supported the growth of the segment.

Among all end users, the hospitals and transplant centers segment accounted for the largest share, holding XX% in the market in 2020. This trend is expected to continue during the forecast period 2021-2031, with the segment anticipated to hold a XX% share in 2031.

The high share of this segment is primarily attributed to the significant increase in the number of organ transplant procedures, rising adoption of organ transplant diagnostic products by the patients due to the presence of favorable reimbursement scenarios, and growing awareness among transplant physicians regarding the clinical utility of organ transplant diagnostics, among others.

Global Organ Transplant Diagnostics Market Snapshot

Global Organ Transplant Diagnostics Market Snapshot

The North America region is expected to dominate the global organ transplant diagnostics market during the forecast period 2021-2031.

The growth in this region can be majorly attributed to the presence of well-established guidelines regarding transplant diagnostics, presence of legacy companies undertaking key business strategies, rising number of organ transplants, and increasing adoption of products based on advanced molecular technologies by the transplant physicians, among others.

Further, increasing focus on research pertaining to the discovery of novel transplant-associated biomarkers is also expected to support the growth of the North America organ transplant diagnostics market during the forecast period, 2021-2031.

The Asia-Pacific region is expected to witness the highest CAGR of XX% during the forecast period, 2021-2031. The growth in the Asia-Pacific market is expected to be further enhanced by other factors, such as an increase in healthcare awareness, a steady economy leading to a higher focus on research, and widespread adoption of organ transplant diagnostic products and services.

Market Overview

Our healthcare experts have found the organ transplant diagnostics industry to be one of the most rapidly evolving and dynamic markets, and the global market for organ transplant diagnostics is predicted to grow at a CAGR of 10.92% over the forecast period of 2021-2031. The market is driven by certain factors, which include rising number of organ transplant procedures, strategic initiatives by key market players, and favorable regulatory scenarios.

Currently, the organ transplant diagnostics industry is witnessing an upsurge due to the rising number of organ transplant procedures, strategic initiatives by key market players, and favorable regulatory scenarios are some of the critical factors which are expected to bolster the market growth.

Furthermore, biotechnology companies are focusing on the development of robust organ transplant diagnostics solutions for applications, including diagnostics and translational research, further supporting transplant physicians and researchers to unravel insights pertaining to the intricacies present in the field of transplant care.

The development of organ transplant diagnostic products and services enabled transplant physicians to establish effective strategies for organ donor screening and recipient surveillance, further offering value-based care.

Within the research report, the market is segmented on the basis of offering, transplant, application, technology, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the number of organ transplant procedures worldwide has created a buzz among the biotechnology companies to further invest in the development of innovative organ transplant diagnostic tools, further aiding transplant physicians to offer value-based clinical outcomes to transplant patients. Due to the expansive product portfolio and massive geographical presence, Thermo Fisher Scientific Inc. has been the leading player in the organ transplant diagnostics ecosystem.

On the basis of region, North America holds the largest share of the organ transplant diagnostics market due to the presence of well-established guidelines regarding transplant diagnostics, presence of legacy companies undertaking key business strategies, rising number of organ transplants, and increasing adoption of products based on advanced molecular technologies by the transplant physicians, among others.

Further, increasing focus on research pertaining to the discovery of novel transplant-associated biomarkers is also expected to support the growth of the North America organ transplant diagnostics market. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2021-2031.

Related reports: Research Report of Organ Transplantation in China 2020-2024

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Base Year

2021

Base Market Size

$3, 427.9 Million in 2021

Currency/Unit

USD

Forecast Year

2031

Market Size Forecast

$9, 663.0 Million by 2031

CAGR

10.92%

Table of Contents

1 Markets
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.2 Market Scope
1.2.1 Scope of the Study
1.2.2 Key Questions Answered in the Report
1.3 Market Overview
1.3.1 Market Definition
1.3.2 Emerging Applications of Organ Transplant Diagnostics
1.3.3 Market Footprint and Growth Potential, $Million, 2020-2031
1.3.4 COVID-19 Impact on the Global Organ Transplant Diagnostics Market
2 Industry Insights
2.1 Overview
2.2 Legal Requirements and Framework in the U.S.
2.2.1 FDA Regulation
2.2.2 CMS Regulation
2.3 Legal Requirements and Frameworks in Europe
2.4 Legal Requirements and Frameworks in Asia-Pacific
2.4.1 China
2.4.2 Japan
2.5 Reimbursement Analysis
3 Market Dynamics
3.1 Overview
3.2 Impact Analysis
3.3 Market Drivers
3.3.1 Rising Number of Organ Transplant Procedure
3.3.2 Strategic Initiatives by Key Market Players
3.3.3 Favorable Regulatory Scenario
3.4 Market Restraints
3.4.1 High Cost of Organ Transplant Procedure and Diagnostics
3.4.2 Lack of Knowledge Dissemination and Reluctance Toward Organ Transplants
3.5 Market Opportunities
3.5.1 Technological Advancement in Transplant Diagnostics
3.5.1.1 Emergence of Nucleic Acid Amplification Testing (NAAT)
3.5.1.2 Growing Focus on Molecular HLA Typing
3.5.2 Increasing Awareness Regarding Transplants in High potential Market
4 Competitive Landscape
4.1 Overview
4.2 Synergistic Activities
4.3 Product Launches
4.4 Product Approvals
4.5 Mergers and Acquisitions
4.6 Other Business Activities
4.7 Market Share Analysis, 2019-2020
4.8 Growth Share Analysis (Company)
5 Offering, $Million, 2020-2031
5.1 Overview
5.2 Products
5.2.1 Kits and Assays
5.2.2 Consumables
5.3 Services
6 Transplant, $Million, 2020-2031
6.1 Overview
6.2 Solid Organ Transplant
6.2.1 Kidney
6.2.2 Liver
6.2.3 Heart
6.2.4 Lung
6.2.5 Pancreas
6.2.6 Kidney-Pancreas
6.2.7 Other Solid Organs
6.3 Stem Cell Transplant
7 Application, $Million, 2020-2031
7.1 Overview
7.2 Diagnostics
7.2.1 Donor Testing
7.2.1.1 Infectious Disease
7.2.1.1.1 Viral
7.2.1.1.2 Bacterial
7.2.1.1.3 Fungal
7.2.1.1.4 Parasitic
7.2.1.2 Human Leukocyte Antigen (HLA) Typing
7.2.1.3 ABO Grouping
7.2.2 Recipient Testing
7.2.2.1 Infectious Disease
7.2.2.1.1 Viral
7.2.2.1.2 Bacterial
7.2.2.1.3 Fungal
7.2.2.1.4 Parasitic
7.2.2.2 Human Leukocyte Antigen (HLA) Typing
7.2.2.3 ABO Grouping
7.2.2.4 Chimerism Testing
7.2.2.5 Graft versus Host Disease (GvHD)
7.3 Translational Research
8 Technology, $Million, 2020-2031
8.1 Overview
8.2 Molecular Technologies
8.2.1 Polymerase Chain Reaction (PCR)
8.2.1.1 Real-Time PCR (RT-PCR)
8.2.1.2 Digital PCR (dPCR)
8.2.2 Sequencing
8.2.2.1 Next-Generation Sequencing (NGS)
8.2.2.2 Sanger Sequencing
8.2.2.3 Other Molecular Technologies
8.3 Serology
8.4 Flow Cytometry (FCM)
8.5 Other Technologies
9 End-User, $Million, 2020-2031
9.1 Overview
9.2 Hospitals and Transplant Centers
9.3 Academic and Research Institutions
9.4 Reference Laboratories
9.5 Other End Users
10 Regions, $Million, 2020-2031
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 U.K.
10.3.4 Italy
10.3.5 Spain
10.3.6 Switzerland
10.3.7 Rest-of-Europe
10.4 Asia-Pacific
10.4.1 China
10.4.2 India
10.4.3 Japan
10.4.4 South Korea
10.4.5 Australia
10.4.6 Singapore
10.4.7 Rest-of-Asia-Pacific (RoAPAC)
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest-of-Latin America (RoLA)
10.6 Rest-of-the-World
11 Company Profiles
11.1 Overview
11.2 Thermo Fisher Scientific Inc.
11.2.1 Company Overview
11.2.2 Role of Thermo Fisher Scientific Inc. in the Global Organ Transplant Diagnostics Market
11.2.3 Financials
11.2.3 Key Insights About Financial Health of the Company
11.2.4 SWOT Analysis
11.3 QIAGEN N.V.
11.3.2 Company Overview
11.3.3 Role of QIAGEN N.V. in the Global Organ Transplant Diagnostics Market
11.3.4 Financials
11.3.5 Key Insights About Financial Health of the Company
11.3.6 SWOT Analysis
11.4 F. Hoffmann-La Roche Ltd.
11.4.2 Company Overview
11.4.3 Role of F. Hoffmann-La Roche Ltd in the Global Organ Transplant Diagnostics Market
11.4.4 Financials
11.4.5 Key Insights About Financial Health of the Company
11.4.6 SWOT Analysis
11.5 Bio-Rad Laboratories, Inc.
11.5.2 Company Overview
11.5.3 Role of Bio-Rad Laboratories, Inc. in the Global Organ Transplant Diagnostics Market
11.5.4 Financials
11.5.5 Key Insights About Financial Health of the Company
11.5.6 SWOT Analysis
11.6 Laboratory Corporation of America Holdings
11.6.2 Company Overview
11.6.3 Role of Laboratory Corporation of America Holdings in the Global Organ Transplant Diagnostics Market
11.6.4 Financials
11.6.5 SWOT Analysis
11.7 bioMérieux S.A.
11.7.2 Company Overview
11.7.3 Role of bioMérieux S.A. in the Global Organ Transplant Diagnostics Market
11.7.4 Financials
11.7.5 Key Insights About Financial Health of the Company
11.7.6 SWOT Analysis
11.8 CareDx, Inc.
11.8.2 Company Overview
11.8.3 Role of CareDx, Inc. in the Global Organ Transplant Diagnostics Market
11.8.4 Financials
11.8.5 Key Insights About Financial Health of the Company
11.8.6 SWOT Analysis
11.9 ARUP Laboratories
11.9.2 Company Overview
11.9.3 Role of ARUP Laboratories in the Global Organ Transplant Diagnostics Market
11.9.4 SWOT Analysis
11.1 Abbott Laboratories
11.10.2 Company Overview
11.10.3 Role of Abbott Laboratories in the Global Organ Transplant Market
11.10.4 Financials
11.10.5 Key Insights About Financial Health of the Company
11.10.6 SWOT Analysis
11.11 Quest Diagnostics Incorporated
11.11.2 Company Overview
11.11.3 Role of Quest Diagnostics Incorporated in the Global Organ Transplant Diagnostics Market
11.11.4 Financials
11.11.5 SWOT Analysis
11.12 Eurofins Scientific
11.12.2 Company Overview
11.12.3 Role of Eurofins Scientific in the Global Organ Transplant Diagnostics Market
11.12.4 Financials
11.12.5 SWOT Analysis
11.13 Illumina, Inc.
11.13.2 Company Overview
11.13.3 Role of Illumina, Inc. in the Global Organ Transplant Diagnostics Market
11.13.4 Financials
11.13.5 Key Insights About Financial Health of the Company
11.13.6 SWOT Analysis
11.14 OPKO Health
11.14.2 Company Overview
11.14.3 Role of OPKO Health in the Global Organ Transplant Diagnostics Market
11.14.4 Financials
11.14.5 Key Insights About Financial Health of the Company
11.14.6 SWOT Analysis
11.15 Novacyt Group
11.15.2 Company Overview
11.15.3 Role of Novacyt Group in the Global Organ Transplant Diagnostics Market
11.15.4 Financials
11.15.5 Key Insights About Financial Health of the Company
11.15.6 SWOT Analysis
11.16 Immucor, Inc,
11.16.2 Company Overview
11.16.3 Role of Immucor, Inc. in the Global Organ Transplant Diagnostics Market
11.16.4 SWOT Analysis
List of Figures
Figure 1: Figure: U.S. Solid Organ and Bone Marrow Transplant Procedures (2017-2020)
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Global Organ Transplant Diagnostics Market
Figure 3: Global Organ Transplant Diagnostics Market (by Offering), $Million, 2020 and 2031
Figure 4: Global Organ Transplant Diagnostics Market (by Transplant), $Million, 2020 and 2031
Figure 5: Global Organ Transplant Diagnostics Market (by Application), $Million, 2020 and 2031
Figure 6: Global Organ Transplant Diagnostics Market (by Technology), $Million, 2020 and 2031
Figure 7: Global Organ Transplant Diagnostics Market (by End Users), $Million, 2020 and 2031
Figure 8: Global Organ Transplant Diagnostics Market Snapshot
Figure 9: Global Organ Transplant Diagnostics Market: Research Methodology
Figure 10: Primary Research Methodology
Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
Figure 12: Top-Down Approach (Segment-Wise Analysis)
Figure 13: Global Organ Transplant Diagnostics Market Segmentation
Figure 14: Global Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 15: Global Organ Transplant Diagnostics Market: COVID-19 Impact Analysis
Figure 16: U.S. Solid Organ and Hematopoietic Stem Cell Transplant Data (2017-2020)
Figure 17: Share of Key Developments and Strategies, January 2018-September 2021
Figure 18: Share of Synergistic Activities (by Company), January 2018-September 2021
Figure 19: Number of Product Launches (by Company), January 2018-September 2021
Figure 20: Share of Product Approvals (by Company), January 2018-September 2021
Figure 21: Share of Mergers and Acquisitions (by Company), January 2018–September 2021
Figure 22: Share of Other Business Activities (by Company), January 2018- September 2021
Figure 23: Market Share Analysis for Global Organ Transplant Diagnostics Market, $Million, 2019 and 2020
Figure 24: Growth Share Analysis for Global Organ Transplant Diagnostics Market (by Company), 2020
Figure 25: Figure 8.1: Global Organ Transplant Diagnostics Market (by Offering)
Figure 26: Global Organ Transplant Diagnostics Market (by Offering), 2020 and 2031
Figure 27: Global Organ Transplant Diagnostics Market (by Product), $Million, 2020-2031
Figure 28: Global Organ Transplant Diagnostics Market (Kits and Assays), 2020-2031
Figure 29: Global Organ Transplant Diagnostics Market (Consumables), $Million, 2020-2031
Figure 30: Global Organ Transplant Diagnostics Market (Services), $Million, 2020-2031
Figure 31: Global Organ Transplant Diagnostics Market (Transplant)
Figure 32: Global Organ Transplant Diagnostics Market (Transplant), 2020 and 2031
Figure 33: Global Organ Transplant Diagnostics Market (by Solid Organ Transplants), $Million, 2020-2031
Figure 34: Global Organ Transplant Diagnostics Market (by Solid Organ Transplant), 2020 and 2031
Figure 35: Global Organ Transplant Diagnostics Market (Kidney, by Solid Organ Transplants), $Million, 2020-2031
Figure 36: Global Organ Transplant Diagnostics Market (Liver, by Solid Organ Transplants), $Million, 2020-2031
Figure 37: Global Organ Transplant Diagnostics Market (Heart, by Solid Organ Transplants), $Million, 2020-2031
Figure 38: Global Organ Transplant Diagnostics Market (Lung, by Solid Organ Transplants), $Million, 2020-2031
Figure 39: Global Organ Transplant Diagnostics Market (Pancreas, by Solid Organ Transplants), $Million, 2020-2031
Figure 40: Global Organ Transplant Diagnostics Market (Kidney-Pancreas, by Solid Organ Transplants), $Million, 2020-2031
Figure 41: Global Organ Transplant Diagnostics Market (Other Solid Organs, by Solid Organs), $Million, 2020-2031
Figure 42: Global Organ Transplant Diagnostics Market (Stem Cell Transplant), $Million, 2020-2031
Figure 43: Global Organ Transplant Diagnostics Market (by Application)
Figure 44: Global Organ Transplant Diagnostics Market (by Application), $Million, 2020-2031
Figure 45: Global Organ Transplant Diagnostics Market (Diagnostics), $Million, 2020-2031
Figure 46: Global Organ Transplant Diagnostics Market (by Diagnostics), 2020 and 2031
Figure 47: Global Organ Transplant Diagnostics Market (Donor Testing), $Million, 2020-2031
Figure 48: Global Organ Transplant Diagnostics Market (by Donor Testing), 2020 and 2031
Figure 49: Global Organ Transplant Diagnostics Market (Infectious Disease, by Donor Testing), $Million, 2020-2031
Figure 50: Global Organ Transplant Diagnostics Market (Infectious Disease, by Donor Testing), 2020 and 2031
Figure 51: Global Organ Transplant Diagnostics Market (Viral, by Donor Testing), $Million, 2020-2031
Figure 52: Global Organ Transplant Diagnostics Market (Bacterial, by Donor Testing), $Million, 2020-2031
Figure 53: Global Organ Transplant Diagnostics Market (Fungal, by Donor Testing), $Million, 2020-2031
Figure 54: Global Organ Transplant Diagnostics Market (Parasitic, by Donor Testing), $Million, 2020-2031
Figure 55: Global Organ Transplant Diagnostics Market (HLA Typing, by Donor Testing), $Million, 2020-2031
Figure 56: Global Organ Transplant Diagnostics Market (ABO Grouping, by Donor Testing), $Million, 2020-2031
Figure 57: Global Organ Transplant Diagnostics Market (Recipient Testing), $Million, 2020-2031
Figure 58: Global Organ Transplant Diagnostics Market (by Recipient Testing), 2020 and 2031
Figure 59: Global Organ Transplant Diagnostics Market (Infectious Disease, by Recipient Testing), $Million, 2020-2031
Figure 60: Global Organ Transplant Diagnostics Market (Infectious Disease, by Recipient Testing), 2020 and 2031
Figure 61: Global Organ Transplant Diagnostics Market (Viral, by Recipient Testing), $Million, 2020-2031
Figure 62: Global Organ Transplant Diagnostics Market (Bacterial, by Recipient Testing), $Million, 2020-2031
Figure 63: Global Organ Transplant Diagnostics Market (Fungal, by Recipient Testing), $Million, 2020-2031
Figure 64: Global Organ Transplant Diagnostics Market (Parasitic, by Recipient Testing), $Million, 2020-2031
Figure 65: Global Organ Transplant Diagnostics Market (HLA Typing, by Recipient Testing), $Million, 2020-2031
Figure 66: Global Organ Transplant Diagnostics Market (ABO Grouping, by Recipient Testing), $Million, 2020-2031
Figure 67: Global Organ Transplant Diagnostics Market (Chimerism Testing, by Recipient Testing), $Million, 2020-2031
Figure 68: Global Organ Transplant Diagnostics Market (GvHD, by Recipient Testing), $Million, 2020-2031
Figure 69: Global Organ Transplant Diagnostics Market (Translational Research), $Million, 2020 – 2031
Figure 70: Global Organ Transplant Diagnostics Market (by Technology)
Figure 71: Global Organ Transplant Diagnostics Market (by Technology), 2020 and 2021
Figure 72: Global Organ Transplant Diagnostics Market (Molecular Technologies), $Million, 2020-2021
Figure 73: Global Organ Transplant Diagnostics Market (by Molecular Technologies), 2020 and 2031
Figure 74: Global Organ Transplant Diagnostics Market (PCR), $Million, 2021-2031
Figure 75: Global Organ Transplant Diagnostics Market (by PCR), 2020 and 2031
Figure 76: Global Organ Transplant Diagnostics Market (RT-PCR, by PCR), $Million, 2020 and 2031
Figure 77: Global Organ Transplant Diagnostics Market (dPCR, by PCR), $Million, 2020 and 2031
Figure 78: Global Organ Transplant Diagnostics Market (Sequencing), $Million, 2020-2031
Figure 79: Global Organ Transplant Diagnostics Market (by Sequencing), 2020 and 2031
Figure 80: Global Organ Transplant Diagnostics Market (NGS, by Sequencing), $Million, 2020-2031
Figure 81: Global Organ Transplant Diagnostics Market (Sanger Sequencing, by Sequencing), $Million, 2020-2031
Figure 82: Global Organ Transplant Diagnostics Market (Other Molecular Technologies), $Million, 2020-2031
Figure 83: Global Organ Transplant Diagnostics Market (Serology), $Million, 2020-2031
Figure 84: Global Organ Transplant Diagnostics Market (Flow Cytometry), $Million, 2020-2031
Figure 85: Global Organ Transplant Diagnostics Market (Other Technologies), $Million, 2020-2031
Figure 86: Global Organ Transplant Diagnostics Market (by End User)
Figure 87: Global Organ Transplant Diagnostics Market (by End User), $Million, 2020 and 2031
Figure 88: Global Organ Transplant Diagnostics Market (Hospitals and Transplant Centres), $Million, 2020-2031
Figure 89: Global Organ Transplant Diagnostics Market (Academic and Research Institutions), $Million, 2020-2031
Figure 90: Global Organ Transplant Diagnostics Market (Reference Laboratories), $Million, 2020-2031
Figure 91: Global Organ Transplant Diagnostics Market (Other End Users), $Million, 2020-2031
Figure 92: Global Organ Transplant Diagnostics Market (by Region): Market Snapshot
Figure 93: Global Organ Transplant Diagnostics Market (by Region), $Million, 2020-2031
Figure 94: Global Organ Transplant Diagnostics Market (by Region), 2020 and 2031
Figure 95: North America Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 96: North America: Market Dynamics
Figure 97: North America Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
Figure 98: U.S. Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 99: Canada Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 100: Europe Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 101: Europe: Market Dynamics
Figure 102: Europe Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
Figure 103: Germany Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 104: France Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 105: U.K. Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 106: Italy Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 107: Spain Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 108: Switzerland Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 109: Rest-of-Europe Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 110: Asia-Pacific Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 111: APAC: Market Dynamics
Figure 112: APAC Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
Figure 113: China Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 114: India Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 115: Japan Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 116: South Korea Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 117: Australia Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 118: Singapore Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 119: RoAPAC Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 120: Latin America Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 121: Latin America: Market Dynamics
Figure 122: Global Organ Transplant Diagnostics Market (by Country), $Million, 2020-2031
Figure 123: Brazil Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 124: Mexico Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 125: RoLA Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 126: RoW Organ Transplant Diagnostics Market, $Million, 2020-2031
Figure 127: Total Number of Companies Profiled
Figure 128: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 129: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
Figure 130: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
Figure 131: : Thermo Fisher Scientific Inc.: Revenue (by region), 2018-2020
Figure 132: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 133: : Thermo Fisher Scientific Inc: SWOT Analysis
Figure 134: QIAGEN N.V.: Product Portfolio
Figure 135: QIAGEN N.V.: Overall Financials, 2018-2020
Figure 136: QIAGEN N.V.: Revenue (by Segment), 2018-2020
Figure 137: QIAGEN N.V.: Revenue (by Region), 2018-2020
Figure 138: QIAGEN N.V.: R&D Expenditure, 2018-2020
Figure 139: QIAGEN N.V.: SWOT Analysis
Figure 140: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 141: F. Hoffmann-La Roche Ltd: Overall Financials, 2018-2020
Figure 142: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2018-2020
Figure 143: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020
Figure 144: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
Figure 145: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 146: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 147: : Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
Figure 148: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
Figure 149: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
Figure 150: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 151: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 152: Laboratory Corporation of America Holdings: Service Portfolio
Figure 153: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
Figure 154: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
Figure 155: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 156: bioMérieux S.A: Product Portfolio
Figure 157: bioMérieux S.A.: Overall Financials, 2018-2020
Figure 158: bioMérieux S.A.: Revenue (by Segment), 2018-2020
Figure 159: bioMérieux S.A.: Revenue (by Region), 2018-2020
Figure 160: bioMérieux S.A.: R&D Expenditure, 2018-2020
Figure 161: bioMérieux S.A.: SWOT Analysis
Figure 162: CareDx Inc.: Product Portfolio
Figure 163: CareDx, Inc.: Overall Financials, 2018-2020
Figure 164: CareDx, Inc.: Revenue (by Segment), 2018-2020
Figure 165: CareDx, Inc.: Revenue (by Region), 2018-2020
Figure 166: CareDx, Inc.: R&D Expenditure, 2018-2020
Figure 167: CareDx, Inc., SWOT Analysis
Figure 168: ARUP Laboratories: Product Portfolio
Figure 169: ARUP Laboratories: SWOT Analysis
Figure 170: Abbott Laboratories: Product Portfolio
Figure 171: Abbott laboratories: Overall Financials, 2018-2020
Figure 172: Abbott Laboratories.: Revenue (by Segment), 2018-2020
Figure 173: Abbott Laboratories: Revenue (by Region), 2018-2020
Figure 174: Abbott Laboratories: R&D Expenditure, 2018-2020
Figure 175: Abbott Laboratories: SWOT Analysis
Figure 176: Quest Diagnostics Incorporated: Product Portfolio
Figure 177: Quest Diagnostics Incorporated: Overall Financials, 2018-2020
Figure 178: Quest Diagnostics Incorporated: Revenue (by Segment), 2018-2020
Figure 179: Quest Diagnostics Incorporated: SWOT Analysis
Figure 180: Eurofins Scientific: Service Portfolio
Figure 181: Eurofins Scientific: Overall Financials, 2018-2020
Figure 182: Eurofins Scientific: Revenue (by Region), 2018-2020
Figure 183: Eurofins Scientific: SWOT Analysis
Figure 184: Illumina Inc, Product Portfolio
Figure 185: Illumina, Inc, Overall Financials, 2018-2020
Figure 186: Illumina, Inc. Revenue (by Segment), 2018-2020
Figure 187: Illumina, Inc.: Revenue (by Region), 2018-2020
Figure 188: Illumina, Inc: R&D Expenditure, 2018-2020
Figure 189: Illumina, Inc: SWOT Analysis
Figure 190: OPKO Health: Product Portfolio
Figure 191: OPKO Health: Overall Financials, 2018-2020
Figure 192: OPKO Health: Revenue (by Region), 2018-2020
Figure 193: OPKO Health: R&D Expenditure, 2018-2020
Figure 194: OPKO Health: SWOT Analysis
Figure 195: Novacyt Group: Product Portfolio
Figure 196: Novacyt Group: Overall Financials, 2018-2020
Figure 197: Novacyt Group.: Revenue (by Segment): 2018-2020
Figure 198: Novacyt Group: R&D Expenditure, 2018-2020
Figure 199: Novacyt Group: SWOT Analysis
Figure 200: Immucor, Inc: Product Portfolio
Figure 201: Immucor, Inc.: SWOT Analysis
List of Tables
Table 1: Key Coverage Providers for Organ Transplant Diagnostics Tests
Table 2: Likert Scale
Table 3: Impact Analysis of Market Drivers
Table 4: Impact Analysis of Market Restraints
Table 5: Companies Providing Kits and Assays:
Table 6: Companies Offering Consumables:
Table 7: Table: Companies Offering Consumables:
Table 8: RT-PCR-Based Organ Transplant Diagnostic Products
Table 9: dPCR-Based Organ Transplant Diagnostic Products
Table 10: NGS-Based Organ Transplant Diagnostic Products
Table 11: Sanger Sequencing-Based Organ Transplant Diagnostic Products
Table 12: Other Technologies-Based Organ Transplant Diagnostic Products
Table 13: Serology-Based Organ Transplant Diagnostic Products
Table 14: FCM-Based Organ Transplant Diagnostic Products